ArticleTransplantation2026
CCL22-expressing Stem Cell-derived Islet Grafts Recruit Regulatory T Cells in Mice.
Article in Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Hidden immune memory niches in inflammatory skin diseases.bioRxiv : the preprint server for biology · 2026Article
- Engineering hypoimmune stem cell-derived beta cells.Stem cell research & therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCell therapy using human donor or stem cell-derived islets (SC-islets) to replace lost insulin-producing beta (β) cells holds great promise for type 1 diabetes. Recruiting regulatory T cells (Treg) through chemokine signaling could mitigate allo- and autoimmune attack on transplanted β-cells, potentially obviating the need for immunosuppressants. We hypothesized that SC-islets genetically engineered to secrete the chemokine C-C motif chemokine ligand 22 (CCL22) would attract Treg to the site of transplantation and may ultimately prolong graft survival.
methodsWe engineered human embryonic stem cells to express CCL22 and differentiated them into SC-islets. CCL22 + SC-islets were assessed for gene and protein markers of endocrine cells and tested for function in vitro by glucose-stimulated insulin secretion assay, and in vivo by transplanting SC-islets into immune-deficient, streptozotocin-treated diabetic mice. Next, CCL22 bioactivity was confirmed by Transwell Treg migration assay. Treg migration was tracked using bioluminescent imaging of mice with CCL22 + SC-islet grafts and infused with luciferase-expressing Treg.
resultsThe expression of CCL22 did not adversely impact the differentiation into SC-islets, as confirmed by gene and protein analysis and functional tests in vitro and in vivo. CCL22 + SC-islets induced Treg migration in vitro, with specificity to CCL22 confirmed by a C-C motif chemokine receptor type 4 antagonist. Furthermore, CCL22 + SC-islet grafts recruited human Treg to the transplant site.
conclusionsCCL22 + SC-islets are functional and capable of attracting Treg. By recruiting Treg, CCL22 + SC-islets may create a tolerogenic immune environment for SC-islets after transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.